Last reviewed · How we verify
Dectomax (DORAMECTIN)
Dectomax, also known as Doramectin, is a parasiticide originally developed by Janssen Pharmaceutica and currently owned by Zoetis. It is a small molecule modality used to treat internal and external parasites in cattle and sheep. Dectomax is not FDA approved for human use, but it is used in veterinary medicine. The commercial status of Dectomax is not publicly disclosed, but it is likely patented. Key safety considerations include potential side effects such as muscle weakness and lethargy in treated animals.
At a glance
| Generic name | DORAMECTIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dectomax CI brief — competitive landscape report
- Dectomax updates RSS · CI watch RSS